Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight loss
Biotech
Zealand slides as Boehringer-partnered obesity drug underwhelms
With the readout echoing earlier data that underwhelmed analysts, shares in Boehringer’s partner Zealand Pharma fell 12% in early trading in Denmark.
Nick Paul Taylor
Oct 1, 2026 6:15am
Lilly sets up next-gen obesity war with phase 3 retatrutide data
Sep 30, 2026 3:06am
Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug
Sep 29, 2026 3:50am
Novo scraps $285M pact with Ascendis to develop monthly GLP-1
Sep 15, 2026 5:19am
Corbus posts obesity data in area where Novo, Sanofi stumbled
Sep 14, 2026 10:07am
Why Roche is 'really excited' about UCN2's obesity potential
Sep 3, 2026 10:47am
